Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

Journal of Clinical Investigation

Volumn 101, Issue 10, 1998, Pages 2290-2296

  Yotnda, Patricia ^a   Firat, Hüseyin ^a   Garcia Pons, François ^a   Garcia, Zacarias ^a   Gourru, Géraldine ^a   Vernant, Jean Paul ^b   Lemonnier, François A ^a   Leblond, Véronique ^b   Langlade Demoyen, Pierre ^a  

^a INSTITUT PASTEUR   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

BCR ABL; Chromosomal translocation; Cytotoxic T lymphocytes; Leukemia; Tumor antigen

Indexed keywords

BCR ABL PROTEIN; EPITOPE; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA B8 ANTIGEN; NONAPEPTIDE; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CELL MEDIATED CYTOTOXICITY; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL;

EID: 0032523810     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI488     Document Type: Article

References (38)

1. Townsend, A., and H. Bodmer. 1989. Antigen recognition by class I-restricted T lymphocytes. Ann. Rev. Immunol. 7:601-624.
2. Greenberg, P.D., M.A. Cheever, and A. Feffer. 1981. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptive transfer. J. Exp. Med. 154:952-963.
3. Leclerc, J.C., and H. Cantor. 1980. T-Cell-mediated immunity to oncornavirus induced tumors. II. Ability of different T cell subsets to prevent tumor growth in vivo. J. Immunol. 124:851-854.
4. Plata, F., P. Langdale-Demoyen, J.-P. Abastado, T. Berbar, and P. Kourilsky. 1987. Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo. Cell. 48:231-240.
5. Cheever, M.A., D.B. Thompson, J.P. Kharnet, and P.D. Greenberg. 1986. Antigen-driven long-term cultured T cells proliferative in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. Exp. Med. 163:1100-1112.
6. Greenberg, P.D., D.E. Kern, and M.A. Cheever. 1985. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+ T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122-1134.
7. Bloomfield, C.D., Z.D. Rowley, A.I. Goldman, S.D. Lawler, J. Secker, L.M. Walker, and F. Mitelman. 1982. Third international workshop on chromosomes in leukemia. Cancer Res. 43:868a (Abstr.)
8. Gale, R.P., and E. Canaani. 1984. An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA. 81:5648-5652.
9. Konopka, J.P., S.M. Watanabe, and O.N. Witte. 1984. An alteration of human c-abl protein in the K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 37:1035-1042.
10. Shtivelman, E., B. Lifshitz, R.P. Gale, and E. Canaani. 1985. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature. 315:550-554.
11. Stam, K., N. Heisterkamp, F.H. Reynolds, Jr., and J. Groffen. 1987. Evidence that the phl gene encodes a 160,000-dalton phosphoprotein. Mol. Cell. Biol. 7:1955-1960.
12. Kloetzer, W., R. Kurzrock, L. Smith, M. Talpas, M. Spiller, R.B. Arlinghaus, and J.U. Gutterman. 1995. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology. 140:230-238.
13. Ben Neriak, Y., G.Q. Daley, A.M. Mes-Masson, O.N. Witte, and D. Baltimore. 1986. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr/abl hybrid gene. Science. 233:212-214.
14. bcr-abl in chronic myelogenous leukemia. Blood. 70:233-236.
15. Canaani, E., C. Marcelle, and E. Fainstein. 1991. BCR-ABL RNA in chronic myelogenous leukemia and acute lymphoblastic leukemia. In Chronic Myelogenous Leukemia: Molecular Approaches to Research and Therapy. Vol. 13. A. Deisserath and R.B. Arlinghaus, editors. Dekker, New York. 217-240.
16. van Denderen, Y., A. Hermans, T. Meenwsen, C. Troelstra, N. Zegers, W. Boersma, G. Grosfeld, and W. van Ewijk. 1989. Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J. Exp. Med. 169:87-98.
17. Chen, W., D.J. Peace, D.K. Rovira, S.G. You, and M.A. Cheever. 1992. T-cell immunity to the joining region of p210 BCR-ABL protein. Proc. Natl. Acad. Sci. USA. 89:1468-1472.
18. Ben Bosch, G.J.A., A.C. Toornvliet, T. Friede, C.J.M. Melief, and O.C. Leeksma. 1995. Recognition of peptides corresponding to the joining region of p210 BCR-ABL protein by human T cells. Leukemia. 9:1344-1348.
19. Cullis, J.O., A.J. Barret, J.M. Goldman, and R.I. Lechler. 1994. Binding of BCR-ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. Leukemia. 8: 165-170.
20. Bocchia, M., P.A. Wentworth, S. Southwood, J. Sidney, K. McGraw, D.A. Scheinberg, and A. Sette. 1995. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 85:2680-2684.
21. Bocchia, M., T. Korontsvit, Q. Xu, S. Mackinnon, S.Y. Yang, A. Sette, and D.A. Scheinberg. 1996. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 87:3587-3592.
22. Ljunggren, H.G., N.J. Stam, C. Ohlen, J.J. Neefjes, P. Höglund, M.T. Heemels, J. Bastin, T.N. Schumacher, A. Townsend, K. Kärre, et al. 1990. Empty MHC class I molecules come out in the cold. Nature. 346:476-480.
23. Langlade-Demoyen, P., J.-P. Levraud, P. Kourilsky, and J.-P. Abastado. 1994. Primary cytotoxic T lymphocyte induction using peptide-stripped autologous cells. Int. Immunol. 6:1759-1766.
24. Celis, E.V., C. Tsai, R. Crimi, P.A. DeMars, R.W. Wentworth, H.M. Chesnut, A. Grey, A. Sette, and H.M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic epitopes. Proc. Natl. Acad. Sci. USA. 91:2105-2109.
25. Lefkovits, I., and H. Waldmann. 1979. Limiting Dilution Analysis of Cells in the Immune System. Cambridge University Press, New York. 262 pp.
26. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614-1620.
27. Rammensee, H.G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
28. + T lymphocytes. J. Immunol. 151:5993-6001.
29. Harding, C.V., and E.R. Unanue. 1990. Ouantitation of antigen presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature. 346:574-576.
30. Christnick, E.R., M.A. Luscher, B.H. Barber, and D.B. Williams. 1991. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature. 352:67-70.
31. Schwartz, R.H. 1989. Acquisition of immunologic self-tolerance. Cell. 57:1073-1081.
32. Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 63:1245-1256.
33. Cibotti, R., J.M. Kanellopoulos, J.P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, and P. Kourilsky. 1992. Tolerance to a self-protein involves its immunodominant but not subdominant peptides. Proc. Natl. Acad. Sci. USA. 89:416-420.
34. Cibotti, R., J.-P. Cabaniols, C. Pannetier, C. Dalarbre, I. Vergnon, J.M. Kanellopoulos, and P. Kourilsky. 1994. Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice. J. Exp. Med. 180:861-872.
35. Fialkow, P.J., R.J. Jacobson, and T. Papayannopoulu. 1977. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte erythrocyte platelet and monocyte/macrophage. Am. J. Med. 63:125-130.
36. Szczylik, C., T. Skorski, N.C. Nicolaides, L. Manzella, L. Malaguarnera, D. Venturelli, A.M. Gewirtz, and B. Calabretta. 1991. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligonucleotides. Science. 253:562-565.
37. Lisker, R., L. Casas, O. Mutchwick, F. Perez-Chavez, and J. Labardini. 1980. Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood. 56:812-814.
38. Bartram, C.R., J.W. Janssen, R. Becher, A. de Klein, and G. Grosveld. 1986. Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis. J. Exp. Med. 164:1398-1404.